Clinical trials: Assessment Evaluation
External Genital Warts
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%.
- Trial name
- NCT02482428
- Testing
- Investigational Treatment, Aldara
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy…
- Trial name
- NCT05894928
- Testing
- LOXO-783, Cholestyramine
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
The purpose of this study is to 1) evaluate the safety and tolerability, and immunogenicity of blinded V114 and Prevnar 13™ within each vaccination group, and 2) evaluate the safety and tolerability, and immunogenicity of…
- Trial name
- NCT03565900
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers
Primary objective: To assess the safety and tolerability of EXPAREL® administered as a single intrathecal injection in healthy volunteers Secondary objective: To characterize the pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT04173611
- Testing
- EXPAREL, Bupivacaine Hydrochloride
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pacira Pharmaceuticals, Inc
Asthma
A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma
This is a non-confirmatory, randomized, subject and investigator blinded, placebo-controlled, parallel-design, multi-center bronchoprovocation study.
- Trial name
- NCT03138811
- Testing
- CSJ117
- Where
- 10 sites in Canada, Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants
The aim of this study is to investigate different formulations of S-337395.
- Trial name
- NCT06270511
- Testing
- S-337395
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shionogi
Meningococcal Disease
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.
- Trial name
- NCT01000311
- Testing
- MenACWY-CRM, DTaP-IPV/Hib, HBV
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Weight Management
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea
The purpose of this study is to evaluate the effect and safety of HRS9531 Injection in Obese Subjects with Obstructive Sleep Apnea
- Trial name
- NCT06565871
- Testing
- HRS9531 Injection
- Volunteers
- 108 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Premature Infants
Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
Compliance to Synagis (palivizumab) is a key factor to obtain maximal protection against respiratory syncytial virus (RSV) infection as shown in the IMpact study.
- Trial name
- NCT01077271
- Where
- 45 sites in Austria
- Volunteers
- 124 people
- Sponsor
- Abbott
Non-Segmental Vitiligo
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Vitiligo is a common, long-lasting disease that happens when the immune system attacks melanocytes (skin cells that produce the skin-coloring pigment melanin) in the skin leading to loss of color.
- Trial name
- Ph3 Peds Viti (NCT07896434)
- Testing
- Upadacitinib
- Volunteers
- 154 people
- Sponsor
- AbbVie
Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus
Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus
The purpose of this clinical trial is to evaluate the safety and efficacy of rhEGF (recombinant human Epidermal Growth Factor) in diabetic foot ulcer patients with uncontrolled diabetes mellitus.
- Trial name
- NCT01629199
- Testing
- rhEGF(recombinant human Epidermal Growth Factor)
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hepatitis B, Hepatitis B Infection
A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites
A prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of the study. Capillary (fingerstick) whole blood and EDTA venipuncture whole blood are collected by a healthcare…
- Trial name
- NCT06368466
- Testing
- iStatis HBsAg Test
- Where
- Australia
- Volunteers
- 175 people
- Sponsor
- bioLytical Laboratories
Diabetes Type 2
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes
The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug…
- Trial name
- NCT01046422
- Testing
- BMS-770767, Metformin
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 76 people
- Sponsor
- Bristol-Myers Squibb
Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial…
- Trial name
- NCT07484022
- Testing
- GB-4362, enfortumab vedotin (EV), Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- Generate Biomedicines
Healthy
Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants
The study will evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamics (PD), and explore the food effect of M5049 in healthy male and female participants.
- Trial name
- NCT03676322
- Testing
- M5049
- Where
- Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Allergic Asthma
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots) and will test the hypothesis that…
- Trial name
- NCT00267202
- Testing
- Omalizumab, Immunotherapy
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis
Contact Lens Wearer
2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses
The objective of this 2 hour study is to evaluate the clinical performance of samfilcon A lenses with an alternate packaging solution (EPG01) compared to commercially available B+L Ultra lenses.
- Trial name
- NCT05126953
- Testing
- samfilcon A Lenses with EPG01 Packaging Solution, Commercially Available B+L Ultra Lenses
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetes
A Performance Evaluation of the Lumiradx Point of Care HbA1c Device
In patients who have diabetes, symptoms of diabetes or attending a diabetic clinic the study will evaluate agreement between the HbA1c measurements from the LumiraDx POC HbA1c assay and the Tosoh G8, as an aid in the monitoring…
- Trial name
- PHADE (NCT05403853)
- Testing
- Venepuncture, Fingerstick
- Where
- 4 sites in United Kingdom
- Volunteers
- 177 people
- Sponsor
- LumiraDx UK Limited
Coronary Artery Disease (Left Main)
Clinical Study to Evaluate the STENTYS Xposition S for Treatment of Unprotected Left Main Coronary Artery Disease
Prospective, non-randomized, multi-center study assessing the long term safety and efficacy of the self expandable sirolimus eluting Xposition S stent in the treatment of unprotected left main coronary artery disease.
- Trial name
- TRUNC (NCT02800837)
- Where
- 4 sites in Italy, Switzerland and 1 more
- Volunteers
- 200 people
- Sponsor
- Stentys
Keloids
Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence
This is a 2-part study. In the first part (Part I, 8 subjects), biopsies will be obtained from the resection site after keloid shaving and two weeks following resection to assess and select biomarkers to determine the biologic…
- Trial name
- NCT00987545
- Testing
- QAX576
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.